Liver fibrosis markers in alcoholic liver disease
- PMID: 25009372
- PMCID: PMC4081671
- DOI: 10.3748/wjg.v20.i25.8018
Liver fibrosis markers in alcoholic liver disease
Abstract
Alcohol is one of the main factors of liver damage. The evaluation of the degree of liver fibrosis is of great value for therapeutic decision making in patients with alcoholic liver disease (ALD). Staging of liver fibrosis is essential to define prognosis and management of the disease. Liver biopsy is a gold standard as it has high sensitivity and specificity in fibrosis diagnostics. Taking into account the limitations of liver biopsy, there is an exigency to introduce non-invasive serum markers for fibrosis that would be able to replace liver biopsy. Ideal serum markers should be specific for the liver, easy to perform and independent to inflammation and fibrosis in other organs. Serum markers of hepatic fibrosis are divided into direct and indirect. Indirect markers reflect alterations in hepatic function, direct markers reflect extracellular matrix turnover. These markers should correlate with dynamic changes in fibrogenesis and fibrosis resolution. The assessment of the degree of liver fibrosis in alcoholic liver disease has diagnostic and prognostic implications, therefore noninvasive assessment of fibrosis remains important. There are only a few studies evaluating the diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with ALD. Several noninvasive laboratory tests have been used to assess liver fibrosis in patients with alcoholic liver disease, including the hyaluronic acid, FibroTest, FibrometerA, Hepascore, Forns and APRI indexes, FIB4, an algorithm combining Prothrombin index (PI), α-2 macroglobulin and hyaluronic acid. Among these tests, Fibrotest, FibrometerA and Hepascore demonstrated excellent diagnostic accuracy in identifying advanced fibrosis and cirrhosis, and additionally, Fibrotest was independently associated with survival. Therefore, the use of biomarkers may reduce the need for liver biopsy and permit an earlier treatment of alcoholic patients.
Keywords: Alcoholic liver disease; Liver fibrosis markers.
Similar articles
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.Hepatology. 2009 Jan;49(1):97-105. doi: 10.1002/hep.22576. Hepatology. 2009. PMID: 19053048
-
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.Gastroenterology. 2018 Apr;154(5):1369-1379. doi: 10.1053/j.gastro.2018.01.005. Epub 2018 Jan 6. Gastroenterology. 2018. PMID: 29317276
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.World J Gastroenterol. 2015 Oct 21;21(39):11044-52. doi: 10.3748/wjg.v21.i39.11044. World J Gastroenterol. 2015. PMID: 26494961 Free PMC article. Review.
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.Eur J Gastroenterol Hepatol. 2014 Apr;26(4):404-11. doi: 10.1097/MEG.0000000000000041. Eur J Gastroenterol Hepatol. 2014. PMID: 24561990
-
Non-invasive diagnosis of advanced fibrosis and cirrhosis.World J Gastroenterol. 2014 Dec 7;20(45):16820-30. doi: 10.3748/wjg.v20.i45.16820. World J Gastroenterol. 2014. PMID: 25492996 Free PMC article. Review.
Cited by
-
Cis-4-[18F]fluoro-L-proline PET/CT molecular imaging quantifying liver collagenogenesis: No existing fibrotic deposition in experimental advanced-stage alcoholic liver fibrosis.Front Nucl Med. 2022 Aug 23;2:952943. doi: 10.3389/fnume.2022.952943. eCollection 2022. Front Nucl Med. 2022. PMID: 39354960 Free PMC article.
-
Machine learning insights concerning inflammatory and liver-related risk comorbidities in non-communicable and viral diseases.World J Gastroenterol. 2022 Nov 28;28(44):6230-6248. doi: 10.3748/wjg.v28.i44.6230. World J Gastroenterol. 2022. PMID: 36504554 Free PMC article. Review.
-
Flightless-I is a potential biomarker for the early detection of alcoholic liver disease.Biochem Pharmacol. 2021 Jan;183:114323. doi: 10.1016/j.bcp.2020.114323. Epub 2020 Nov 7. Biochem Pharmacol. 2021. PMID: 33166508 Free PMC article.
-
Trends in the management and burden of alcoholic liver disease.J Hepatol. 2015 Apr;62(1 Suppl):S38-46. doi: 10.1016/j.jhep.2015.03.006. J Hepatol. 2015. PMID: 25920088 Free PMC article. Review.
-
Alpha Mangostin Inhibits the Proliferation and Activation of Acetaldehyde Induced Hepatic Stellate Cells through TGF-β and ERK 1/2 Pathways.J Toxicol. 2018 Nov 14;2018:5360496. doi: 10.1155/2018/5360496. eCollection 2018. J Toxicol. 2018. PMID: 30538742 Free PMC article.
References
-
- Lieber CS. Medical disorders of alcoholism. N Engl J Med. 1995;333:1058–1065. - PubMed
-
- Lieber CS. Alcoholic liver injury: pathogenesis and therapy in 2001. Pathol Biol (Paris) 2001;49:738–752. - PubMed
-
- Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346:987–990. - PubMed
-
- Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol. 2005;3:167–174. - PubMed
-
- Worner TM, Lieber CS. Perivenular fibrosis as precursor lesion of cirrhosis. JAMA. 1985;254:627–630. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous